CYP2D6 metabolism frailty
Conditions
Interventions
Assesment of CYP2D6 phenotype by 13C-dextromethorphan breath test
Sponsors
Leids Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria * Men and women aged 70-85 years * Body-mass index between 20 and 30 kg/m2
Exclusion criteria
Exclusion criteria: Exclusion Criteria * Presence of acute illness * Presence of metastasized cancer * CYP2D6 poor metabolizer genotype * Inability or unwillingness to fast overnight prior to the study session. * Inability or willingness to abstain from drinking alcohol for 24 h prior to the DM-BT. * A diagnosis of pulmonary disease such as asthma or other respiratory disease associated with hypercapnia. * Existence of metabolic or gastrointestinal disorders which influence absorption and/or gastric emptying. * A demonstrated adverse reaction to previous dextromethorphan exposure. * Impaired hepatic function as defined by * Grade 3 AST, alkaline phosphatase or total bilirubin or a history of liver cirrhosis * Stage III renal insufficiency defined by a MDRD of
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main parameters obtained in the determination of CYP2D6 clinical phenotype by 13C-DM-BT. Parameters concerning CYP2D6 clinical phenotype which are collected:: - DOB values on t=0-120 - AUCDOB0-120 - Cumulative percentage of dose recovery (cPDR) | — |
Secondary
| Measure | Time frame |
|---|---|
| - sex - race - age - length - body weight - body mass index (BMI) - smoking status - use of concomitant medication - concomitant disease - parameters on frailty: walking speed, grip strength, weight loss, energy expenditure, - Mini mental state examination (MMSE), questionnaire on all-day-living (ADL) and mood (HADS-1) | — |
Countries
Netherlands
Outcome results
None listed